Company news
Imugene Ltd (ASX:IMU) news
Imugene Ltd news releases on 6ix. Latest, Feb 12, 2021: Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial
Press releases — page 4
Imugene Commences Cohort 2 Dosing in Phase 1 PD1-VAXX Trial
February 11, 2021
Imugene Dose Escalates in PD1-VAXX Phase 1 Clinical Trial
January 20, 2021
IMUGENE COMPLETES RECRUITMENT TO HER-VAXX PHASE 2 TRIALIM
January 6, 2021
Imugene Enrols First Cohort of PD1-Vaxx Clinical Trial
December 16, 2020
Imugene Receives $4.82 million R&D Tax Incentive
December 10, 2020
Imugene First Patient Dosed in PD1-VAXX Clinical Trial
November 30, 2020
Imugene HER Vaxx shows positive Overall Survival in trial
November 22, 2020
Imugene Receives FDA IND Approval for PD1-VAXX Trial in USA
November 1, 2020
Imugene Immunotherapy Combination Patent Granted in US
October 1, 2020
Imugene Secures $5.7 million Option Underwriting Agreement
September 8, 2020
Imugene Receives PD1-VAXX Ethics Trial Approval in USA
September 3, 2020
Appendix 4E & Annual Report to shareholders
August 31, 2020
Imugene Receives Third PD1-VAXX Ethics Trial Approval
August 20, 2020
Imugene Receives Clinical Guidance from US FDA for Vaxinia
August 5, 2020
Imugene Receives Second PD1-VAXX Ethics Trial Approval
July 16, 2020
Imugene Receives Ethics Approval to Start PD1-VAXX Trial
July 13, 2020
Imugene HER-Vaxx Phase 2 Clinical Update
May 3, 2020
Imugene PD1-Vaxx Immunotherapy Update
January 27, 2020
Imugene HER-Vaxx Immunotherapy Patent Granted in US
January 13, 2020
Imugene Share Placement to raise $24.6 million
December 1, 2019
Imugene Receives $4.13 million R&D Tax Incentive
November 4, 2019
US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy
October 22, 2019
CF33 Oncolytic Virus Clinical Trial Program Update
October 20, 2019
Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO
September 30, 2019
Investor Presentation - Proposed Acquisition
July 14, 2019
New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI
July 7, 2019
Appendix 4C - Quarterly and Business Update
April 15, 2019
IMU presents new mimotope PD-1 vaccine data at AACR
April 2, 2019
IMU presents new KEY-Vaxx and B-Vaxx data at AACR
April 1, 2019
IMU Pre-IND FDA Meeting Provides Guidance for KEY-Vaxx
March 19, 2019
Imugene doses first patient in HER-Vaxx phase 2 trial
March 13, 2019
IMU Announces Presentations on KEY-Vaxx and B-Vaxx at AACR
March 3, 2019
Pause in Trading
February 27, 2019
IMU Meets Endpoints in Phase 1b Gastric Cancer Trial
December 16, 2018
Imugene Advances to Phase 2 in Gastric Cancer Trial
November 12, 2018
Imugene Receives $1.85 million R&D Tax Incentive
November 8, 2018
Imugene commences cGMP manufacture of PD-1 cancer vaccine
September 20, 2018
Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment
September 10, 2018
Appendix 4E and Audited Financial Report
August 31, 2018
PD-1 cancer vaccine development update
July 22, 2018
IMUGENE RAISES $20.1 MILLION
June 7, 2018
Imugene Licences Extensive B-Cell Immuno-Oncology Portfolio
June 6, 2018
Leslie Chong Appointed as Managing Director
March 27, 2018
Arginine Modulator Active in Cancer Models
February 18, 2018
Novel Anti-PD-1 Mimotope Vaccine Ready for Development
February 11, 2018
IMU Meets Investigator for Gastric Cancer Clinical Trial
February 8, 2018
Cancer vaccine shows early promise in clinical trial
February 6, 2018
Business Update - December Quarter Appendix 4C
January 28, 2018
Rights Issue Results & Shortfall Notification
December 19, 2017
IMUGENE RAISES $8.7 MILLION
November 22, 2017